Pharma Videos

Coiled Therapeutics' Dr Sotirios Stergiopoulos on Roquefort RTO, AO-252 Cancer Trial Update

Coiled Therapeutics announced a reverse takeover of Roquefort Therapeutics, effectively relisting the clinical‑stage oncology company on the London market under the Coiled name. The transaction involves licensing the proprietary acid‑based drug AO‑252 from A2A Pharmaceuticals and raising £8.5 million to finance its next development phase. The newly raised capital will be directed almost entirely toward expanding the ongoing Phase I trial, targeting enrollment of 30‑50 patients by mid‑Q3 2026. Early data have shown tumor reductions with an exceptionally clean safety profile—no bone‑marrow suppression or liver toxicity—addressing a key limitation of existing chemotherapies for prostate and ovarian cancers. Dr. Sotirios Stergiopoulos highlighted that AO‑252’s safety enables longer continuous dosing and opens combination‑therapy opportunities, positioning the molecule as a potential monotherapy alternative to traditional chemotherapy. He also noted that successful trial read‑outs could trigger discussions with large pharmaceutical partners and broaden the drug’s indication landscape. If the trial confirms efficacy, AO‑252 could reshape solid‑tumor treatment by offering a less toxic option, attracting strategic alliances, and delivering value to shareholders through a differentiated oncology pipeline.